2015我国胃癌治疗现状_第1页
2015我国胃癌治疗现状_第2页
2015我国胃癌治疗现状_第3页
2015我国胃癌治疗现状_第4页
2015我国胃癌治疗现状_第5页
已阅读5页,还剩47页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Challenge for Surgeons in CHINA Current situation and future trends,Jiafu Ji MD, PhD, FACS,Tumor burden,Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Inter

2、net. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http:/globocan.iarc.fr, accessed on day/month/year.,2012,2035,325k,667k,Economical Burden,韩启德 关于医学技术发展的价值思考,Chinese feature,CSCO. Gastric Cancer Survey.2011,EGC 10.8%,MGC 31.2%,Locally Advanced GC 58.0%,20.5%,77.6%

3、,1.8%,Data from PKUCH, 2013.8-2014.9,Treatment algorithm in PKUCH,MDT-Digital management,Surgery for EGC,EMR/ESD 39.5%,LAP 29.9%,OP 30.7%,Therapeutic options of EGC,The Trends of EMR/ESD in Beijing Cancer Hospital, 2011-2013,Annual Growth: 22%,Video: PKUCH, Department of Endoscopy,Expanding boundary

4、 of ESD,The renovation of treatment strategy demands for better Accuracy and Comprehensiveness in clinical staging,Data from PKUCH, 2013.8-2014.9,pT1 88.7%,pN+ 8.2%,New challenge,Current trends: SLN Navigation,Dye through serosa,JCOG 0302,missed pN+,46.4%,1.Te99: 1day before surgery 2.Dye: during su

5、rgery,Endoscopic Dual-tracer,SN(-)/non-SN(+)1%,Accuracy: 99%,*“Sentinel Lymph Node Biopsy”mesh Node May 23. Lee HK et al. Br J Surg 2001 ;88:1408-1412. Yoh et al. Gastric Cancer 2011; 14:301-316. JiJF et al. Chin J Prac Surg 2011; 8:38-43.,Ji JF. Chin J Cancer Res. 2010; 22(3):167-175,Same method, D

6、ifferent prognosis,Accordance between cStage and pStage: 53.4%,Data from PKUCH, Clinical Trial,Limitation: clinical staging,Data from PKUCH, Clinical Trial,Limitation: clinical staging,Reversed Survival,CT,EUS,Limitation: clinical staging,Pathology,Limitation: clinical staging,Positive Rate in cM0 P

7、atients 15.7%(113/718),Staging laparoscopy + Cytology,Photo Takashi et al, Cancer J. 2007.,Distant Local Peritoneal,Part I: Recur. patternstrategy,19个省市 48家单位 ,Data: RESOLVE Trial, 2014,Ongoing: RESOLVE(NCT01534546),Li ZY,Ji JF*, et al . Journal of Surgical Oncolgy 2011, DOI 10.1002/jso.23009,Unsati

8、sfied response,NACRT 45Gy/25f,NACRT for EGJ: experience,Randomization,Radiotherapy GTV 50 Gy CTV 45 Gy Chemotherapy OXA 40 mg/m2/d1,8,15,22,29 S-1 30 mg/m2 bid d1-d5/w,no,Surgery Total Gastrectomy D2lymphadenectomy,Chemotherapy OXA 130mg/m2/d1 Q3w S-1 40-60mg bid d1-d14 Q3w 6-8cycles,Group A(neo CRT

9、) n=128,Group B(surgry) n=128,Response evaluation,Preoperative chemoradiotherapy followed by surgery and adjuvant chemotherapy compared with surgery and adjuvant chemotherapy for local advanced adenocarcinoma of the esophagogastric junction,RCT Phase III trial LAGC, EGJ Primary Outcome: 3-year DFS S

10、econdary Outcome: 5-year OS Registration: NCT02193594,Ongoing: CRADLE (NCT02193594),Till 2015.4, our center has enrolled XX patient, accounts for XX% as planed. NACRT: Surgery: NACRT: 2 patient has undergone surgery.,Ongoing: CRADLE (NCT02193594),Pathology and perioperative outcome,Part II: LAP for

11、GC,CLASS-01 trial: LAP for LAGC,Data: CLASS Trial,CLASS-01 trial - Multicenter RCT On Lap. Distal Subtotal Gastrectomy for Advanced Gastric Cancer (NCT01609309),LAP after NACT,Postoperative recovery: LAPOP,Complication: LAP=OP,Radical degree: LAP=OP,20,Data from PKUCH, 2012.9-2014.3,Randomization,Gr

12、oup A(LAP) n=48,Adjuvant CT OXA 130mg/m2/d1 Q3w Capecitabine 1000mg/m2 bid d1-d14 Q3w 5 cycles,Neoadjuvant Chemotherapy OXA 130mg/m2/d1 Q3w Capecitabine 1000mg/m2 bid d1-d14 Q3w 3 cycles,Primary outcome 3-yearDFS Secondary outcome: 5-yearOS,Laparoscopic versus open distal gastrectomy for locally adv

13、anced gastric cancer after neoadjuvant chemotherapy,Group B(OPEN) n=48,Ongoing: REALIZATION(NCT02404753),Surgery for MGC,Data: PKUCH, 2013.8-2014.9,Diagnosis Tools,LAP 84.9%,CT 15.1%,Area of metastasis,Peritoneal 72.6%,Ovary 13.7%,No.16 LN 6.8%,Liver 5.5%,Distribution of MGC in surgery Dpt.,?,MGC =

14、Forbidden Zone?,ECF trial (2002)1,REAL-2 trail (2008)2,ML17032 trail (2009)3,V325 trail (2008)4,1.Ross P, et al. J Clin Oncol 2002;20:1996-2004; 2.Cunningham D, et al. N Engl J Med. 2008 Jan 3;358(1):36-46. 3. Kang YK, et al; Ann of Oncol, 2009, 20:666-673. 4. Cutsem EV,et al; JCO, 2006,24(31):4991-

15、4997,OS(Month),First-line chemotherapy for MGC: an overview,LESS than 1 year,Slow progress in Chemo for MGC,Data: Konstantinos Lasithiotakis et al. ANTICANCER RESEARCH 34: 2079-2086 (2014),Comparison for palliative surgery through time,Improvement in palliative surgery,Conversion Therapy,Adjuvant Su

16、rgery,Surgical Conception On Oncology,Contradictory Evidence,Sun et al. BMC Cancer 2013. Konstatinos Lasithiotakis et al. Anticancer Research. 2014.,Total gastrectomy may affect chemotherapy appliance,Our Experience with Liver Meta.,Survival of GC with liver metastasis Chemo+Surgery vs. Chemo alone,

17、Survival analysis,Cox regression,Our Experience with Liver Meta.,Survival of GC with liver metastasis Gastrectomy vs. Gastrectomy+metastasectomy,Survival Analysis,Our Experience with Liver Meta.,1st Laparoscopy,2nd Laparoscopy,HIPEC + Chemo,Photo: PKUCH, Department of GI Surgery,Exploration & HIPEC,

18、Survival of GC with peritoneal carcinomatosis,Cumulative Survival (%),Overall Survival (month),CRS + HIPEC For PC: Our Experience,CRS + HIPEC For PC: experience,Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis: SHOP-G01 trial (NCT01471132),Clinical Trial Cy+/P+,Data: PKUCH, Department of GI Surgery,CRS +

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论